AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study

Recruitingn/aAges 6 Years - 17 YearsAllFondation Ophtalmologique Adolphe de Rothschild
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Myopia and high myopia are the leading causes of visual impairment and blindness worldwide. The total number of myopic people globally was estimated to be 2.6 billion in 2020, and it could reach 4.8 billion by 2050 unless preventive interventions are implemented. Strategies to slow the progression of myopia, such as contact lenses, orthokeratology, atropine, and increased time spent outdoors, have shown promising results, although evidence varies depending on the method. However, most research has been conducted in Asia, and there are few studies on ocular growth in myopic children in Europe. Meanwhile, the prevalence of myopia is also increasing significantly in Europe, particularly in France. Understanding the growth of the myopic eye in European children is crucial. Cohort studies of myopic children are scarce and do not always include high-quality imaging. A cohort of myopic childr

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Myopia in at least one eye, defined as a refractive error in spherical equivalent โ‰ค -0.50 diopters (autorefraction under cycloplegia) * Affiliated or beneficiary of a social security system * Explicit consent from a holder of parental authority Exclusion Criteria: * Presence of trauma in both eyes * Presence of inflammatory conditions in both eyes * History of intraocular surgery (cataract, filtering surgery, intra-vitreal surgery) in both eyes * Patient benefiting from legal protection measures
๐Ÿ’Š

What it tests

  • ophtalmologic follow-up
  • ophtalmological follow-up
๐Ÿ“

Where

1 site
Hรดpital Fondation A. de Rothschild
Paris, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy